1 / 10

Le armi terapeutiche per il trattamento della Fibrosi Cistica: nuove acquisizioni

UNITA’ OPERATIVA DI PEDIATRIA Centro Regionale per la diagnosi, la cura e la riabilitazione della Fibrosi Cistica. Le armi terapeutiche per il trattamento della Fibrosi Cistica: nuove acquisizioni. 09/11/2013. Donatello SALVATORE. CF Foundation: le linee di ricerca terapeutica.

andie
Télécharger la présentation

Le armi terapeutiche per il trattamento della Fibrosi Cistica: nuove acquisizioni

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UNITA’ OPERATIVA DI PEDIATRIA Centro Regionale per la diagnosi, la cura e la riabilitazione della Fibrosi Cistica Le armi terapeutiche per il trattamento della Fibrosi Cistica: nuove acquisizioni 09/11/2013 Donatello SALVATORE

  2. CF Foundation: le linee di ricerca terapeutica clinicaltrials.gov cff.org

  3. How much CFTR is enough? Pancreatic Insufficient CF Pancreatic Sufficient Carriers Normal ≈ 30% CFTR activity associated with symptom reduction Adapted from Accurso et al JCF 2013 in press

  4. CF is Not One Genetic DisorderCFTR mutation classes Cl- Cl- Cl- Cl- Cl- Cl- Cl- Cl- Cl- Cl- X X X X X Normal Class I synthesis Class II maturation Class III regulation Class IV conductance Class V quantity ‘severe’ mutations ‘mild’ mutations pancreatic insufficiency pancreatic sufficiency Adapted from http://www.umd.be/CFTR/W_CFTR/gene.html

  5. So, there must be mutation specific treatment approaches Reduced Quantity Reduced Function Normal CFTR quantity and function Little to no CFTR Some CFTR Gating Conductance Class I Class II Class III Class IV Class V Treatment approaches Correctors Potentiators MacDonald et al. Pediatr Drugs 2007;9:1-10; Zielenski. Respiration 2000;67:117-33; Welsh et al. Cystic fibrosis In: Valle et al, eds. OMMBID. McGraw-Hill Companies Inc;2004:part 21,chap 201; O’Sullivan et al. Lancet 2009;373:1891-1904

  6. Class I nonsense mutations Nonsense mutation Readthrough compound Full-length protein Shortened protein Adapted from Schmitz A, Famulok M. Nature 2007

  7. Mean Relative Change in %-Predicted FEV1 at Week 48 by Chronic Baseline Inhaled Antibiotic Use No Inhaled Antibiotics Any Inhaled Antibiotics Week 48 ∆ = 6.7% p = 0.013* Week 48 ∆ = 0.0% p = 0.88* In 2014, PTC is initiating an ataluren Phase 3 efficacy and safety trial in patients not receiving inhaled aminoglycosides *Nominal p-values See Abstract 193

  8. Therapeutic Approaches by Class F508del CFTR Processing Corrector Adapted from New Engl J Med 352(19): 1992-2001, 2005

  9. CFTR proteins with Class II mutations do not reach the cell surface Cl- Cl- Cl- Cl- Cl- Cl- Cultured F508del/F508del-human bronchial epithelial cells X cilia cytoplasmic F508del CFTR F508del Class II mutation nuclei Normal CFTR Van Goor et al., PNAS 2011

  10. Lumacaftor increases the amount of F508del-CFTR at the cell surface Cultured F508del/F508del-human bronchial epithelial cells cilia CFTR nuclei untreated + lumacaftor Van Goor et al., PNAS 2011

More Related